Liver cancer drug trial halted after just 3 patients
NCT ID NCT05103904
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug lenvatinib in people whose liver cancer came back after a liver transplant. The goal was to see if the drug could shrink tumors. Only 3 people joined before the study was stopped early, so we have very limited information on how well it works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Mayo Clinic Arizona
Scottsdale, Arizona, 85259, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- AI takes on liver cancer: could a computer help pick the right immunotherapy?
- Immunotherapy combo tested against untreatable liver cancer
- New drug zanzalintinib tested for advanced liver cancer
- Liver cancer drug combo shows promise in large trial
- New hope for liver cancer patients with cirrhosis? tiny trial tests drug duo